News

Improving the Reimbursement Landscape for Medical Technology Innovators

CBSA continues to work with Congress and federal policymakers to improve the reimbursement landscape for medical technology innovators. Even when groundbreaking and innovative technologies meet FDA’s rigorous standards, device manufacturers face other significant hurdles in navigating the coverage and reimbursement process. In fact, many technology manufacturers do not pursue national coverage decisions because they are too time consuming and cumbersome.

Given the challenges our companies face around reimbursement, we wanted to share a survey that has been designed by our partners at the Medical Device Manufacturers Association (MDMA) to support our efforts to improve the route to coverage.

We strongly encourage you to complete this survey so we are able to provide policymakers with data about the real-world implications for patients and providers.

PLEASE CLICK HERE TO TAKE THIS SURVEY ABOUT YOUR COMPANY'S EXPERIENCES WITH THE PUBLIC AND PRIVATE REIMBURSEMENT SYSTEMS.

 



Go Back